Pfizer Wins Tafamidis Approval; Now It Will Need To Build The Market

 
• By Jessica Merrill

Tafamidis was approved by FDA in two formulations that will be marketed as Vyndaqel and Vyndamax for the treatment of transthyretin amyloid cardiomyopathy.

Start background, Top view of Businessman on Start line, Business Challenge or do something new - Image

More from New Products

More from Scrip